Physician profile
Brant Wayne Thomas
NPI 1730155862
$8,458.78
in general payments reported to CMS, 2019-2025
28 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,943 · 2020: $271 · 2021: $1,703 · 2022: $1,479 · 2023: $891 · 2024: $907 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,189.92 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $994.25 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $950.99 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $846.83 | 2019-2024 | Mounjaro, Kisunla |
| Sanofi-Aventis U.S. LLC | $756.32 | 2019-2024 | |
| Novo Nordisk INC | $645.43 | 2019-2022 | |
| Astellas Pharma US INC | $417.01 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $362.36 | 2021-2024 | |
| Amarin Pharma, INC. | $279.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $247.25 | 2019-2021 | |
| Eisai INC. | $245.28 | 2023-2025 | |
| Abbvie INC. | $225.04 | 2021-2023 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.92 | 2019-2020 | |
| Esperion Therapeutics, INC. | $176.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $138.93 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $124.93 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $124.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $124.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.37 | 2022 | |
| Biogen, INC. | $98.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $52.57 | 2021 | |
| Merck Sharp & Dohme LLC | $29.52 | 2019 | |
| Mylan Specialty L.P. | $28.12 | 2019-2020 | |
| Corcept Therapeutics | $22.65 | 2019 | |
| Scpharmaceuticals INC. | $18.68 | 2025 | |
| Pfizer INC. | $17.40 | 2020 | |
| Allergan, INC. | $12.97 | 2020 | |
| Boston Scientific Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brant Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.